However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy
Bleeding Events Up With Full-Dose Thromboprophylaxis in COVID-19
Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation
Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically ill patients hospitalized for COVID-19
Therapeutic Heparin May Benefit Moderately Ill COVID-19 Inpatients
Among those with increased D-dimer levels, no reduction seen in primary composite outcome at 28 days, but odds of death decreased
Antithrombotic Therapy Not Helpful for COVID-19 Outpatients
Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients
Outpatient Anticoagulant Therapy May Cut COVID-19 Admission Risk
COVID-19 inpatients not on anticoagulants before or after hospitalization have increased risk for mortality
COVID-19 Outcomes in Critically Ill No Better With Full-Dose Heparin
For patients hospitalized with COVID-19 who are not critically ill, therapeutic-dose anticoagulation is beneficial
ASH Suggests Not Using Outpatient Thromboprophylaxis for COVID-19
For discharged patients without suspected or confirmed VTE or other indication for anticoagulation, panel suggests not using anticoagulants
Prophylactic Anticoagulation Aids Hospitalized COVID-19 Patients
Prophylactic-dose anticoagulation, but not treatment-dose anticoagulation, associated with lower 60-day mortality
Guidance Issued for Managing CVST After COVID-19 Vaccination
CVST with thrombocytopenia reported after COVID-19 vaccine with adenoviral vector; management similar to heparin-induced thrombocytopenia
- Page 1 of 2
- 1
- 2